12 May 2022, Double Tree Tower Bridge, London

08.00 – 09.00

Registration & refreshments

08.30 – 09.15

Breakfast Briefing (optional)

09.30 – 09.40

Opening remarks from the chair

09.40 – 10.10

Keynote & Policy Update: NHS Long Term Plan and the Health & Care Bill – what are the implications for cancer?

  • Update on the Galleri trial
  • What does the Health & Care Bill mean for cancer care and treatment pathways?
  • How integrated care, as a strategy, overcomes the fragmentations in care for people with complex needs
  • 62 day cancer waiting target and the two week wait – why do we keep missing these key metrics? If it's not due to Covid, how do we explain it?
  • How is the roll out of rapid diagnostic centres progressing?
  • Further funding streams for the cancer drugs fund
10.10 – 10.50

Panel: Rising to the challenge of a post pandemic recovery

  • Adopting a ‘whole system’ thinking encompassing new treatments for better outcomes, reduce toxicity, and simplifying administration
  • What has the Covid pandemic taught us about collaboration? How do we embed this in practice?
  • Leveraging advances in telemedicine and remote consultations
  • Artificial intelligence and wearables for remote patient monitoring to deliver patient convenience and service efficiencies
  • Expanding drive through services and self-administered treatments at home
  • How more tolerable treatments (oral and subcutaneous delivery) can increase throughput, ease capacity issues, and improve the patient experience

Panellists: 
Speaker to be confirmed, Novartis
Liz Bishop, Chief Executive, Clatterbridge Cancer Centre NHS Foundation Trust
Speaker to be confirmed, Macmillan

 

10.50 – 11.20

Morning break for refreshments & networking

11.20 – 12.20

Interactive Discussion Groups

Interactive roundtable discussions, each 25 mins duration, so attendees can choose 2 of the following topics:

  1. Innovative payment models for rare cancers
    Moderator to be confirmed, GSK
     
  2. Digital technologies to accelerate diagnosis rates and improve system efficiency
     
  3. NICE drop in ad Q&A – priorities and strategies for cancer treatments
     
  4. Optimising prostate cancer treatment
     
  5. What can we learn from the successful roll out of the HPV vaccine?
    Moderator to be confirmed, Novartis
     
  6. AI technologies to revolutionise cancer care
    Moderator to be confirmed, Gilead Sciences
12.20 – 12.25

Transition

12.25 – 13.05

Panel: Tackling inequality in cancer care and treatment

  • What is the patient experience? And the relationship between patient and care giver?
  • Equality of voice, and the input from frequently ignored communities/patient groups
  • Improving access to services, and the ability to self-manage
  • How do we allocate resources optimally to address these inequalities in care and treatment?

Moderator: Dr Véronique Walsh, General Manager, UK & Ireland & Vice President, Gilead Sciences

13.05 – 14.05

Lunch

14.05 – 14.45

Panel: Making community diagnostics work

  • Building multi-disciplinary teams and nurse-led services
  • Supporting the separation of acute and elective diagnostics, providing capacity away from the hospital setting
  • Managing the community diagnostics workforce effectively
  • Leveraging digital technologies to optimise efficiency and administration
14.45 – 15.20

Panel: How Cancer Alliances are improving care, services and outcomes

  • Stakeholders, governance, accountability, and transparency
  • Benefits of local and ‘place-based’ planning for cancer care and diagnostics
  • How Cancer Alliances are set in the context of Sustainability & Transformation Partnerships (STPs) and their five-year plans
  • Impact of Cancer Alliances on reducing inequality of care

Panellists: 
David Shackley, Medical Director, Greater Manchester Cancer & Clinical Lead, Manchester Academic Health Science Centre (MAHSC) & Consultant, Salford Royal NHS Foundation Trust
Amanda Pleavin, Managing Director, East of England Cancer Alliance

 

15.20 – 15.50

Afternoon break for refreshments & networks

15.50 – 16.20

How Cheshire & Merseyside Radiology Imaging Network (CAMRIN) is developing Rapid Diagnostics Services (RDS)

  • Reviewing cancer imaging across the network
  • Optimising pathways and protocols
  • Integrating education and training where required
  • What results are we seeing so far?

David White, Clinical Lead, Cheshire & Merseyside Imaging Network

Advances in lung cancer care and treatment: Stereotactic ablative radiotherapy (SABR)

  • Service configuration and service access
  • Examining outcomes and the patient experience

Dr Neil Bayman, Medical Director, The Christie NHS Foundation Trust

16.25 – 16.30

Transition

16.30 – 17.00

Optimising breast cancer screening services

  • Communication with local populations and communities
  • Making screening more accessible

Developments and breakthroughs in cancer gene therapy

  • Why should we focus on gene therapy?
  • Experimental treatments to target resistant cancers
  • Developing gene therapies to target pancreatic, prostrate and ovarian cancers
  • Identifying predictive biomarkers for virus activity
  • Host immune responses
  • Pathways for gene therapy treatments

    Clare Turnbull, Professional of Translational Cancer Genetics, Institute of Cancer Research & Consultant in Clinical Cancer Genetics, Royal Marsden NHS Foundation Trust
17.00 – 17.05

Transition

17.05 – 17.45 

Closing Panel: Building the cancer workforce, for now and the future

  • What does Health Education England say about the cancer workforce plan?
  • Opportunities for retraining and upskilling your staff
  • Creating new routes into the cancer workforce e.g. level 6 in diagnostic radiography
  • Increasing capacity through international recruitment
  • Exploring approaches to improve staff retention
  • How might the work done by the National Breast Imaging Academy be replicated in other areas?

Panellists:
Dr Mary Wilson, Consultant Breast Radiologist, Manchester University NHS Foundation Trust & Clinical Lead, National Breast Imaging Academy
Phil Carver, Director, Health Education England
Speaker to be confirmed, Macmillan

 

17.45 – 17.50

Closing remarks from the chair

 

download programme  register